Amgen continues to defend Tavneos as global regulatory pressure mounts
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the…
Read the full articleYou might also wanna read
Regulators push Amgen to withdraw drug due to data manipulation
Questions raised over safety and efficacy of Tavneos (avacopan)
Amgen's PCSK9 Patent Battle: Legal Loss but Commercial Victory
In 2014, Amgen sued Sanofi and Regeneron to claim ownership of an entire class of cholesterol drugs. Nine years later, the Supreme Court rul
alexkesin.com·9mo ago
STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more
U.S. judge blocked a Colorado state panel from placing a cap on the price of Amgen's blockbuster drug Enbrel
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
The company recently wowed investors with clinical trial results.
STAT+: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug
A federal judge blocked a Colorado state panel from placing a cap on the price of Enbrel, a blockbuster drug sold by Amgen
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
Comments
Sign in to join the conversation.
No comments yet. Be the first.